Equitech-Bio Expands Reagent Portfolio with New IgG Offering

Equitech-Bio, a trusted supplier of serum proteins and immunoglobulins, has expanded its reagent portfolio with the introduction of a new reagent-grade immunoglobulin gamma (IgG) product. Leveraging Bioz, Inc., a scientific marketing platform that transforms peer-reviewed research into evidence-rich product experiences, Equitech-Bio aims to provide researchers with more reliable and scientifically validated options.

The new IgG offering will complement Equitech-Bio's existing portfolio, which includes a wide range of immunoglobulins from various animal species, antisera, bovine serum albumin (BSA), and other biological reagents. This expansion is particularly beneficial for laboratories conducting research and development workflows that require high consistency, purity, and performance.

Equitech-Bio's decision to integrate its new reagent-grade IgG with Bioz's publication-backed evidence highlights the company's commitment to transparent product evaluation. According to Dakota Howell, Vice President of Sales and Marketing at Equitech-Bio, "Researchers need more than a product specification; they need confidence that a reagent can perform in the applications that matter to them. Bioz helps us place peer-reviewed evidence directly beside the products, giving customers a clearer, faster way to evaluate their options and move forward with confidence."

Bioz Badges, embedded on individual product webpages, transform published product citations into an interactive research experience. Scientists can review relevant article excerpts, explore how a reagent has been used in published experiments, and view Bioz Stars ratings without interrupting the product-evaluation process. The Bioz Content Hub brings Equitech-Bio's broader publication record together in one searchable location, helping researchers navigate efficiently to the products most relevant to their work.

Equitech-Bio's portfolio supports a wide range of experimental and manufacturing needs, including custom and species-specific antisera solutions and multiple grades and purification formats of BSA for various applications such as assay development, cell culture, diagnostics, and protein stabilization. The company's animal IgG selection spans numerous species and formats, enabling researchers to identify products suited to their specific protocols.

The Bioz platform updates continuously as new peer-reviewed research becomes available, giving Equitech-Bio a dynamic way to support both established products and new launches with current scientific evidence. This approach helps Equitech-Bio's sales and marketing teams understand which products, applications, and publications are generating the greatest interest.

Dr. Karin Lachmi, Co-Founder and Chief Revenue Officer at Bioz, commented, "Equitech-Bio's decision to connect its new reagent-grade IgG and core reagent portfolios with publication-backed evidence reflects a strong commitment to transparent product evaluation. Whether scientists are selecting antisera, BSA, or an animal IgG product, Bioz gives them immediate access to evidence that can help them make informed decisions with greater confidence."

With over 30 years of commitment to the research industry, Equitech-Bio supplies high-quality biological reagents to laboratories, diagnostic manufacturers, academic institutions, and biotechnology and pharmaceutical organizations worldwide. The company's comprehensive portfolio supports a broad spectrum of research and development needs, ensuring consistency, dependable performance, responsive service, and flexible ordering options.